To evaluate whether the mutations that strengthen the RBDOmic–ACE2 interaction affect the RBD-targeting COVID-19 therapeutic antibodies, we constructed structural models of eight monoclonal antibodies (mAbs) bound to RBDOmic. Here, ACE2 is linked to COVID-19.